Roche Pays $425 Million for GeneWEAVE, a Decheng Portfolio Company

Roche will acquire GeneWEAVE BioSciences, a Los Gatos, CA diagnostics company, for $425 million. Roche will pay $190 million up front and up to $235 million in milestones. GeneWEAVE’s Smarticles technology develops innovative molecular diagnostics that identify multidrug-resistant organisms (MDROs) along with their susceptibility to specific antibiotics, without requiring additional enrichment. Decheng Capital, a Shanghai healthcare investment firm, is the lead investor and largest shareholder in GeneWEAVE. More details.... Stock Symbol: (SIX: RO, ROG) Share this with colleagues: // //